MORRISTOWN, N.J., Nov. 8 /PRNewswire/ -- Bayer Corporation is advising
consumers that Alka-Seltzer Plus Liqui-Gels and Alka-Seltzer antacid/pain
relief products do not and have never contained phenylpropanolamine (PPA). In
light of the FDA's announcement on Monday, November 6th, Bayer Corporation
yesterday began voluntarily discontinuing U.S. marketing of all Alka-Seltzer
Plus effervescent cold/cough products containing PPA.
"Alka-Seltzer Plus enjoys one of the greatest brand loyalties. We want to
assure consumers that Alka-Seltzer Plus Liqui-Gel products, which do not
contain PPA, can provide the same effective relief they have come to expect
from our other cough/cold products," said Timothy Hayes, Bayer Consumer Care
Region Head, North America. Hayes adds that Bayer looks forward to
introducing reformulated effervescent cough/cold products as soon as possible
in 2001.
The company also advises that its new Aleve Cold & Sinus medicine does not
contain PPA.
Bayer Corporation is a research-based company with major businesses in
health care and life sciences and chemicals. The company had 1999 sales of
$8.9 billion and employs approximately 22,000 people. Bayer Corporation is
investing $9 billion in capital expenditures and research and development from
2000 through the year 2004. 2000 capital investment and R&D expenditures are
projected to total $1.6 billion. Bayer Corporation, with headquarters in
Pittsburgh, is a member of the worldwide Bayer Group, a $29 billion
international life sciences, polymers and specialty chemicals group based in
Leverkusen, Germany.
SOURCE Bayer Corporation
 back to top
Related links:
http://www.bayerus.com
Company News On-Call:
http://www.prnewswire.com/comp/092575.html or fax,
800-758-5804, ext. 092575
CONTACT:
Anne Coiley of Bayer, 973-254-4607
|
